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Clinical Practice Points 
 
The acquired haemophilia is a rather rare and life-threatening disease. In some cases 
the acquired haemophilia develops as a paraneoplastic syndrome of different malignancies. 
Acquired haemophilia caused by ureteral tumour has not been reported previously. 
The treatment of acquired haemophilia has two main goals. First, to achieve 
haemostasis during the bleeding period, and second, to decrease the risk of bleeding by 
eradication of the inhibitor. 
Our patient had haematuria caused by ureteral tumour. Nephroureterectomy was 
performed, but following the operation continuous bleeding was observed.  Due to this we 
administered blood transfusions and performed reoperations, but we couldn’t stop the 
bleeding. 
Later we realised that the prolonged activated partial thromboplastin time was caused 
by the low activity of factor VIII (2%), which proved acquired haemophilia. 
For this reason we administered activated prothrombin complex concentrate and 
recombinant activated factor VII. Three months after the initial operation, an immune-
tolerance induction treatment was administered, after which the activity of factor VIII 
reverted normal.  
 
 
Key words: ureteral tumour, acquired haemophilia, factor VIII deficiency  
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Introduction 
 
Acquired (anti-body) haemophilia is a rather rare and often lethal illness. The main 
feature of the clinical picture is that anti-bodies are formed against one of the coagulation 
factors, most often against factor VIII, which neutralizes the function of the clotting factors 1-
3
.  
The incidence of acquired haemophilia is 0.2-1.48 cases/ million/year. The mortality 
rate of the disease is high and varies between 8 and 44% 2,4-6. Death generally occurs within a 
few weeks due to bleeding. 
In this publication we report the case of acquired factor VIII haemophilia caused by 
ureteral tumour and review the literature. To the best of our knowledge acquired haemophilia 
caused by ureteral tumour has not been published previously.  
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Case report 
 
Our 54-year-old female patient’s case history includes appendectomy, tonsillectomy 
and conization. She was not a known haemophiliac and had no family history of haemophilia.  
The patient had renal pain on the right side, and recurrent hematuria, which started 2  
months earlier. Urological examinations revealed an ureteral tumour in the right ureter, which 
caused stasis in the kidney. Based on these results an ureteronephrectomy was performed on 
the right side using the transperitoneal approach.  The histology showed urothelial papillary 
carcinoma pT1 Grade II.  
Before the operation the patient’s Hb level was 9.4 g/dl, activated partial 
thromboplastin time (APTT): 64.9 s. A blood test showed a platelet count 397 G/L, an INR of 
0.93, a prothrombin time of 7.8 seconds, and a thrombin time of 17.4 seconds. As a result of 
her bleeding tumour she was given multiple blood transfusions and fresh frozen plasma before 
the operation.  
After the operation, the patient continued bleeding  profusely from the wounds, and 
consequenly received blood transfusions and fresh frozen plasma on several occasions.  
By  the 5th post-operative day the patient`s hemoglobin level had dropped to 6.9 g/dl,  
and ultrasound showed an 8x3 cm sized haematoma in the kidney bed and some free fluid in 
the Douglas cavity. For this reason an urgent surgical exploration was done, with no source of  
bleeding found, however a diffuse bloody leakage was observed in the abdomen. 
Between the initial operation and the 2nd reoperation she was given 8 units of blood 
transfusion and 4 units of fresh frozen plasma.  
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Due to the continous bleeding and the isolated APTT extension a mixing test was performed, 
but the APTT was still prolonged. Thereafter we ruled out the presence of lupus anticoagulant 
and determined the activity of the coagulation factors. The result, by the 6th postoperative day 
showed acquired haemophilia. Factor VIII activity was 2 % ( normal value: 60-150 %).  
Consequently activated prothrombin complex concentrate (Factor VIII inhibitor bypassing 
activity agent – FEIBA - 100 Unit/kg every 12 hours) was administered. As a result of this 
treatment bleeding from the wound practically ceased. Her haemoglobin level varied between 
10.2 to 12.4 g/dl. However, on the 12th postoperative day the patient suddenly developed 
shock for which treatment was given. The patient`s hemoglobin level decreased to 7.9 g/dl, 
while ultrasound showed free abdominal fluid and haematomas.  
Urgent reoperation was again performed on the same day. During the operation a significant 
quantity of blood was found in the abdomen and removed. The source of bleeding had no 
surgical origin. 
As a result, the patient received a treatment of recombinant activated factor VII ( dose: 90 
ug/kg/2 hours ). She became stable with no further bleeding tendencies. 
One month after the nephroureterectomy APTT was 87.9 s and factor VIII activity 
was under 1 %.  
Three months after the nephroureterectomy the patient received an immune-tolerance 
induction treatment  for her acquired anti-body haemophilia, in accordance with the Budapest 
Protocol (consisting of human factor VIII concentrate, cyclophosphamide and 
methylprednisolone)7 . 
A month later, the laboratory control tests showed APTT at 38.4 s and factor VIII activity at 
71% (normal range: 60-150%).  The administered immune-tolerance induction treatment  to 
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eradicate the anti-body proved effective, as the involved clotting factor activity became 
normal. 
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Discussion 
 
Acquired haemophilia is a very rare illness associated with a high mortality rate due to 
the life-threatening bleeding condition which does not respond to conventional treatment. 
In approximately 10% of the cases there is a tumour in the background of acquired 
haemophilia. These malignancies can be both haematological and solid tumours 1-3,8-10 . 
Amongst acquired haemophilia related to solid tumours the most common ones are  
lung and prostate cancers, which are each present in 25% of the cases 2,3. 
To the best of our knowledge, acquired haemophilia caused by ureteral tumour has not 
been reported in the literature.   
Acquired haemophilia can occur either before the diagnosis of tumor or after the 
surgery 2. 
During the diagnosis of the most common acquired haemophilia, when anti-body is 
produced against factor VIII, a rise in the activated partial thromboplastin time (APTT) 
isolated expansion can be detected, which cannot be corrected by giving fresh frozen plasma.  
A mixing test combining the patient’s plasma with a normal plasma will show whether 
the prolonged APTT is the result of an intrinsic factor deficiency or an inhibitor ( Figure 1). If 
a clotting factor inhibitor is suspected, the sample mixture should be incubated at 37 °C for at 
least one hour, since inhibitors are generally dependent on both time and temperature. 
If the APTT normalized during the mixing test, an deficiency of clotting factor is the 
cause. If the APTT shows failure to correct, first the role of lupus anticoagulant has to be 
excluded, thereafter the FVIII activity and the inhibitor titer should be determined. 
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Our patient had a normal prothrombin time, and thrombin time, with the platelet level being in 
the normal range. Her factor VIII activity is low.  
The treatment of acquired haemophilia has two main goals. First, to achieve 
haemostasis during the bleeding period, and second, to reduce the risk of bleeding by 
eradication of the inhibitor 1,2,6,8,9. 
To achieve the required haemostasis we can either increase the level of factor VIII or 
use  an agent that bypasses the intrinsic coagulation pathway.  
The routinely administered bypassing agents are activated prothrombin complex 
concentrate (FEIBA) and recombinant  factor VIIa. 
Due to the fact that bleeding can occur at any time while the antibodies are present, it is 
generally accepted that eradication of the inhibitors is necessary in acquired haemophilia. 
To eradicate the anti-body immunsuppressive drugs (prednisolone, cyclophosphamide, 
cyclosporine, immunglobulin, vincristin, mycophenolate, azathioprin) can be used, in addition 
to applying monoclonal antibody, plasmapheresis, immunadsorption, and immune-tolerance 
therapy 9. 
Conclusion 
In the present case, the acquired antibody haemophilia caused by ureteral tumour was 
diagnosed in a the postoperative  period. The patient suffered from serious, lethal bleeding, 
necessitating management with blood transfusions, fresh frozen plasma, and including two 
reoperations. After the diagnosis of acquired haemophilia, activated prothrombin complex 
concentrate  and recombinant factor VIIa treatment were applied, which helped achieve 
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appropriate haemostasis. Acquired haemophilia due to ureteral tumour has not been reported 
previously. 
In conclusion, acquired haemophilia caused by malignancies is very rare but life-
threatening. Based on this case, when the patient has bleeding which does not respond to 
conventional treatment and the APTT shows isolated extension we have to think of acquired 
haemophilia. 
 
 
Legend for Figure 
 
Figure 1.  Algorithm for the diagnosis and treatment of acquired haemophilia 
 
BC: blood count, APTT: activated partial thromboplastin time, PT: prothrombin time, TT: 
thrombin time 
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